A detailed history of Mackenzie Financial Corp transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 23,799 shares of XERS stock, worth $80,202. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,799
Holding current value
$80,202
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.06 - $2.96 $49,025 - $70,445
23,799 New
23,799 $67,000
Q1 2024

May 10, 2024

BUY
$2.04 - $3.22 $19,169 - $30,258
9,397 Added 36.17%
35,375 $78,000
Q2 2023

Aug 03, 2023

BUY
$1.82 - $2.98 $47,279 - $77,414
25,978 New
25,978 $68,000

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $458M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Mackenzie Financial Corp Portfolio

Follow Mackenzie Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.